Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2020

Open Access 01-12-2020 | Affective Disorder | Research

Personalising psychotherapies for depression using a novel mixed methods approach: an example from Morita therapy

Authors: Holly Victoria Rose Sugg, Julia Frost, David A. Richards

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

Current quantitative methods for personalising psychotherapies for depression are unlikely to be able to inform clinical decision-making for hundreds of years. Novel alternative methods to generate hypotheses for prospective testing are therefore required, and we showcase mixed methods as one such approach. By exploring patients’ perspectives in depth, and integrating qualitative and quantitative data at the level of the individual, we may identify new potential psychosocial predictors of psychotherapy outcomes, potentially informing the personalisation of depression treatment in a shorter timeframe. Using Morita therapy (a Japanese psychotherapy) as an exemplar, we thus explored how Morita therapy recipients’ views on treatment acceptability explain their adherence and response to treatment.

Methods

The Morita trial incorporated a pilot randomised controlled trial of Morita therapy versus treatment as usual for depression, and post-treatment qualitative interviews. We recruited trial participants from general practice record searches in Devon, UK, and purposively sampled data from 16 participants for our mixed methods analysis. We developed typologies of participants’ views from our qualitative themes, and integrated these with quantitative data on number of sessions attended and whether participants responded to treatment in a joint typologies and statistics display. We enriched our analysis using participant vignettes to demonstrate each typology.

Results

We demonstrated that (1) participants who could identify with the principles of Morita therapy typically responded to treatment, regardless of how many sessions they attended, whilst those whose orientation towards treatment was incompatible with Morita therapy did not respond to treatment, again regardless of treatment adherence and (2) participants whose personal circumstances impeded their opportunity to engage in Morita therapy attended the fewest sessions, though still benefitted from treatment if the principles resonated with them.

Conclusions

We identified new potential relationships between “orientation” and outcomes, and “opportunity” and adherence, which could not have been identified using existing non-integrative methods. This mixed methods approach warrants replication in future trials and with other psychotherapies to generate hypotheses, based on typologies (or profiles) of patients for whom a treatment is more or less likely to be suitable, to be tested in prospective trials.

Trial registration

Current Controlled Trials, ISRCTN17544090. Registered on 23 July 2015.
Appendix
Available only for authorised users
Literature
1.
McManus S, Bebbington P, Jenkins R, Brugha T. Mental health and wellbeing in England: Adult Psychiatric Morbidity Survey 2014. Leeds: NHS Digital; 2016.
2.
Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–105.PubMed
3.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.PubMed
4.
Marcus M, Yasamy MT, Van Ommeren M, Chisholm D, Saxena S. Depression: a global public health concern. WHO Dep Mental Health Subst Abuse. 2012;1:6–8.
5.
Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013;12(2):137–48.PubMedPubMedCentral
6.
Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol. 2008;76(6):909.PubMed
7.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–42.PubMed
8.
IAPT. IAPT three-year report. The first million patients. London: Department of Health; 2012.
9.
Amick HR, Gartlehner G, Gaynes BN, Forneris C, Asher GN, Morgan LC, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015. https://​doi.​org/​10.​1136/​bmj.​h6019.
10.
Depression Guideline Panel. Clinical practice guideline. Number 5. Depression in primary care. Rockville: Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993.
11.
DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):409–16.PubMed
12.
Jarrett R, Rush JA. Short-term psychotherapy of depressive disorders: current status and future directions. Psychiatry. 1994;57(2):115–32.PubMed
13.
Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, et al. Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet. 2016;388(10047):871–80.PubMedPubMedCentral
14.
Pence BW, O’Donnell JK, Gaynes BN. The depression treatment cascade in primary care: a public health perspective. Curr Psychiatry Rep. 2012;14(4):328–35.PubMedPubMedCentral
15.
Cahill J, Barkham M, Hardy G, Rees A, Shapiro DA, Stiles WB, et al. Outcomes of patients completing and not completing cognitive therapy for depression. Br J Clin Psychol. 2003;42(2):133–43.PubMed
16.
Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry. 2004;184(6):526–33.PubMed
17.
Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatr. 2010;167(12):1445–55.PubMed
18.
Cuijpers P. Personalized treatment for functional outcome in depression. Medicographia. 2014;36(4):476–81.
19.
Cuijpers P, Reynolds CF, Donker T, Li J, Andersson G, Beekman A. Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depress Anxiety. 2012;29(10):855–64.PubMed
20.
Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry. 2009;66(2):128–33.PubMed
21.
22.
Cuijpers P, Christensen H. Are personalised treatments of adult depression finally within reach? Epidemiol Psychiatric Sci. 2017;26(1):40–2.
23.
Cuijpers P, Ebert DD, Acarturk C, Andersson G, Cristea IA. Personalized psychotherapy for adult depression: a meta-analytic review. Behav Ther. 2016;47(6):966–80.PubMed
24.
Jain FA, Hunter AM, Brooks JO, Leuchter AF. Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depress Anxiety. 2013;30(7):624–30.PubMed
25.
DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L. The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One. 2014;9(1):e83875.PubMedPubMedCentral
26.
Kessler R, Van Loo H, Wardenaar K, Bossarte R, Brenner L, Ebert D, et al. Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. Epidemiol Psychiatric Sci. 2017;26(1):22–36.
27.
Molenaar PC, Campbell CG. The new person-specific paradigm in psychology. Curr Dir Psychol Sci. 2009;18(2):112–7.
28.
Hill CE, Chui H, Baumann E. Revisiting and reenvisioning the outcome problem in psychotherapy: an argument to include individualized and qualitative measurement. Psychotherapy. 2013;50(1):68–76.PubMed
29.
Prainsack B. Personhood and solidarity: what kind of personalized medicine do we want? Per Med. 2014;11(7):651–7.PubMed
30.
31.
Addis ME, Jacobson NS. Reasons for depression and the process and outcome of cognitive–behavioral psychotherapies. J Consult Clin Psychol. 1996;64(6):1417.PubMed
32.
Wittink MN, Morales KH, Cary M, Gallo JJ, Bartels SJ. Towards personalizing treatment for depression: developing treatment values markers. Patient. 2013;6(1):35–43.PubMedPubMedCentral
33.
Stewart M, Brown JB, Weston WW, McWhinney IR, McWilliam CL, Freeman TR. Patient-centered medicine: transforming the clinical method. 2nd ed. Oxon: Radcliffe Publishing; 2003.
34.
Hamilton KE, Dobson KS. Cognitive therapy of depression: pretreatment patient predictors of outcome. Clin Psychol Rev. 2002;22(6):875–93.PubMed
35.
Winter SE, Barber JP. Should treatment for depression be based more on patient preference? Patient Prefer Adherence. 2013;7:1047.PubMedPubMedCentral
36.
Britten N. Qualitative research and the take-up of evidence-based practice. J Res Nurs. 2010;15(6):537–44.
37.
Borglin G. The value of mixed methods for researching complex interventions. In: Richards DA, Hallberg IR, editors. Complex Interventions in Health: An overview of research methods. Oxon, New York: Routledge; 2015. p. 29–45.
38.
Sugg HVR, Richards DA, Frost J. Optimising the acceptability and feasibility of novel complex interventions: an iterative, person-based approach to developing the UK Morita therapy outpatient protocol. Pilot Feasibility Stud. 2017;3(1):37.PubMedPubMedCentral
39.
Morita S, Kondo A, LeVine P. Morita therapy and the true nature of anxiety-based disorders (Shinkeishitsu). New York, NY: State University of New York Press; 1998.
40.
Ogawa B. Desire For Life: The practitioner’s introduction to Morita therapy. Indiana: Xlibris Corporation; 2013.
41.
Kitanishi K. The philosophical background of Morita therapy: its application to therapy. In: Tseng WS, Chang SC, Nishizono M, editors. Asian culture and psychotherapy. Honolulu, HI: University of Hawaii Press; 2005. p. 169–85.
42.
Krech G. The art of taking action: lessons from Japanese psychology. Monkton: ToDo Institute; 2014.
43.
44.
Sugg HVR, Richards DA, Frost J. Morita therapy for depression (Morita Trial): a pilot randomised controlled trial. BMJ Open. 2018;8(8):e021605.PubMedPubMedCentral
45.
Sugg HVR, Frost J, Richards DA. Morita therapy for depression (Morita Trial): an embedded qualitative study of acceptability. BMJ Open. 2019;9(5):e023873.PubMedPubMedCentral
46.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.PubMedPubMedCentral
47.
Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. Thousand Oaks: Sage; 2007.
48.
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.PubMed
49.
Ware JE, Kosinski M, Dewey JE, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: Quality Metric Inc.; 2000.
50.
Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. BJPsych. 2002;180(5):461–4.PubMed
51.
Richards DA, Mullan EG, Ishiyama FI, Nakamura K. Developing an outcome framework for measuring the impact of Morita therapy: a report from a consensus development process. J Morita Ther. 2011;22(2):165–73.
52.
Hill JJ, Kuyken W, Richards DA. Developing stepped care treatment for depression (STEPS): study protocol for a pilot randomised controlled trial. Trials. 2014;15(1):452.PubMedPubMedCentral
53.
54.
55.
Ritchie J, Lewis J, Nicholls CM, Ormston R. Qualitative research practice: a guide for social science students and researchers. 2nd ed ed. Los Angeles, London, New Delhi, Singapore: Sage; 2013.
56.
Onwuegbuzie AJ, Leech NL. Sampling designs in qualitative research: making the sampling process more public. Qual Rep. 2007;12(2):238–54.
57.
Miles MB, Huberman AM, Saldana J. Qualitative data analysis: a methods sourcebook. 3rd ed ed. Los Angeles, London, New Delhi, Singapore: Sage; 2014.
58.
Bryman A. Social research methods. 5th ed. ed. Oxford: Oxford University Press; 2016.
59.
Teddlie C, Yu F. Mixed methods sampling: a typology with examples. J Mixed Methods Res. 2007;1(1):77–100.
60.
O'Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services research. J Health Serv Res Policy. 2008;13(2):92–8.PubMed
61.
Fetters MD, Freshwater D. The 1+ 1= 3 integration challenge. J Mixed Methods Res. 2015;9(2):115–7.
62.
Guetterman TC, Fetters MD, Creswell JW. Integrating quantitative and qualitative results in health science mixed methods research through joint displays. Ann Fam Med. 2015;13(6):554–61.PubMedPubMedCentral
63.
64.
Nilsson T, Svensson M, Sandell R, Clinton D. Patients’ experiences of change in cognitive–behavioral therapy and psychodynamic therapy: a qualitative comparative study. Psychother Res. 2007;17(5):553–66.
65.
Simons AD, Lustman PJ, Wetzel RD, Murphy GE. Predicting response to cognitive therapy of depression: the role of learned resourcefulness. Cogn Ther Res. 1985;9(1):79–89.
66.
Bennett-Levy J, Richards D, Farrand P, Christensen H, Griffiths K, Kavanagh D, et al. Oxford Guide to low intensity CBT interventions. Oxford, New York: Oxford University Press; 2010.
67.
Lovell K, Richards D. Multiple access points and levels of entry (MAPLE): ensuring choice, accessibility and equity for CBT services. Behav Cogn Psychother. 2000;28(4):379–91.
68.
May C, Montori VM, Mair FS. We need minimally disruptive medicine. BMJ. 2009;339:b2803.PubMed
69.
Solomonov N, Barber J. What we know, what we do not know, and where are we heading? Efficacy and acceptability of psychological interventions for depression. Epidemiol Psychiatric Sci. 2016;25(4):301–8.
Metadata
Title
Personalising psychotherapies for depression using a novel mixed methods approach: an example from Morita therapy
Authors
Holly Victoria Rose Sugg
Julia Frost
David A. Richards
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3788-3

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue

Study protocol

Short-term fasting accompanying chemotherapy as a supportive therapy in gynecological cancer: protocol for a multicenter randomized controlled clinical trial

Study protocol

Effects of multidomain versus single-domain training on executive control and memory in older adults: study protocol for a randomized controlled trial

Study protocol

The efficacy of Narrative Exposure Therapy for Children (KIDNET) as a treatment for traumatized young refugees versus treatment as usual: study protocol for a multi-center randomized controlled trial (YOURTREAT)

Study protocol

The smoking cessation in pregnancy incentives trial (CPIT): study protocol for a phase III randomised controlled trial

Study protocol

Intratympanic versus intravenous corticosteroid treatment for sudden sensorineural hearing loss in diabetic patients: proposed study protocol for a prospective, randomized superiority trial

Letter

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial